Trial reportBritish journal of cancer2007
Clinical pharmacodynamic factors in docetaxel toxicity.
Trial report in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the impacts of docetaxel and paclitaxel based neoadjuvant therapies on early postoperative complications in HER2-positive breast cancer patients.World journal of surgical oncology · 2026Article
- Low-Dose Docetaxel Is Effective in Reducing Atherogenic Lipids and Atherosclerosis.International journal of molecular sciences · 2025Article
- A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients.Cancer chemotherapy and pharmacology · 2024Article
- A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients.Current drug metabolism · 2024Article
- A pharmacometrics model to define docetaxel target in early breast cancer.British journal of clinical pharmacology · 2023Article
- Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients.Annals of translational medicine · 2022Article
- Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.Clinical pharmacokinetics · 2020Review
- Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.Drugs & aging · 2019Article
- Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.CPT: pharmacometrics & systems pharmacology · 2018Article
- Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.Scientific reports · 2018Article
- Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.The pharmacogenomics journal · 2016Article
- A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials.Cell chemical biology · 2016Article
- Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.European journal of clinical pharmacology · 2016Article
- Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Cancer science · 2015Review
- Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.CPT: pharmacometrics & systems pharmacology · 2015Article
- Effects of tobacco smoking and nicotine on cancer treatment.Pharmacotherapy · 2012Review
- A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.Investigational new drugs · 2012Article
- Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.Investigational new drugs · 2011Article
- Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.British journal of clinical pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutropenia is the main dose-limiting toxicity occurring in docetaxel treatment. The objective of this study was to identify pharmacodynamic (PD) factors responsible for the neutropaenia caused by docetaxel. Data were obtained from 92 patients treated with docetaxel as a monochemotherapy in two different treatment centres. A semiphysiological population pharmacokinetic-pharmacodynamic (PK/PD) model was applied to describe the time course of neutrophils and the neutropaenic effect of docetaxel. The plasma docetaxel concentration was assumed to inhibit the proliferation of neutrophil precursors through a linear model: Drug effect=Slope x Conc. Slope corresponds to the patients' sensitivity to the neutropaenic effect of docetaxel. Covariate analysis was performed by testing the relationship between the patients' characteristics and Slope using the program NONMEM. The neutropaenic effect of docetaxel showed a high interindividual variability. Three significant PD covariates were identified: serum alpha1-acid glycoprotein levels (AAG), level of chemotherapy pretreatment, and treatment centre. Extensive pretreatment was associated with an increase in Slope values meaning a higher haematotoxicity. An increase in AAG was associated with a decrease of both Slope and docetaxel plasma clearance. Patients treated in one centre had both higher Slope and docetaxel clearance. The centre effect (most likely due to a bias in the PK part of the study between the two centres) reveals the robustness of the PK/PD model. Individual dosing of docetaxel should be based on previous chemotherapy but not on the AAG level since it has a similar influence on PD and PK docetaxel parameters. This methodology should be applied to further investigate elderly patients and to identify more precisely the characteristics of previous chemotherapy that contribute to the cumulative myelotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.